Company Overview
About Leap Therapeutics
Leap Therapeutics, Inc. (Nasdaq: LPTX) is a biopharmaceutical company developing targeted therapies for cancer patients with DKK1-expressing tumors. The company's lead candidate, sirexatamab (DKN-01), is an anti-DKK1 antibody in clinical trials for various cancer types, including gastric, colorectal, endometrial, prostate, and lung cancer.